{"id":496272,"date":"2020-07-15T18:38:01","date_gmt":"2020-07-15T18:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496272"},"modified":"2020-07-15T18:38:01","modified_gmt":"2020-07-15T18:38:01","slug":"non-muscle-invasive-bladder-cancer-pipeline-insight-2020","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/non-muscle-invasive-bladder-cancer-pipeline-insight-2020_496272.html","title":{"rendered":"Non Muscle Invasive Bladder Cancer Pipeline Insight, 2020"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>(ALBANY, US) DELVEINSIGHT HAS LAUNCHED A NEW REPORT ON&nbsp;Non Muscle Invasive Bladder Cancer Pipeline<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-muscle-invasive-bladder-cancer-pipeline-insight\" target=\"_blank\">Non Muscle Invasive Bladder Cancer Pipeline<\/a><\/strong> Insight, 2020&nbsp;report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Non Muscle Invasive Bladder Cancer&nbsp;market. A detailed picture of the&nbsp;Non Muscle Invasive Bladder Cancer&nbsp;pipeline landscape is provided, which includes the disease overview and&nbsp;Non Muscle Invasive Bladder Cancer&nbsp;treatment guidelines.<\/p>\n<p style=\"text-align: justify;\">The assessment part of the report embraces in-depth&nbsp;Non Muscle Invasive Bladder Cancer&nbsp;commercial assessment and clinical assessment of the&nbsp;Non Muscle Invasive Bladder Cancer&nbsp;pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology,&nbsp;Non Muscle Invasive Bladder Cancer&nbsp;collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/18c1ba7118422e91f763a46da979e34b.png\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\"><strong>Request For Free Sample Page<\/strong>:-&nbsp;<strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/non-muscle-invasive-bladder-cancer-pipeline-insight\">https:\/\/www.delveinsight.com\/sample-request\/non-muscle-invasive-bladder-cancer-pipeline-insight<\/a><\/span><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><span style=\"text-decoration: underline;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-muscle-invasive-bladder-cancer-pipeline-insight\" target=\"_blank\">Non Muscle Invasive Bladder Cancer Pipeline<\/a><\/span><\/strong><strong>development activities&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The report provides insights into:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>All of the companies that are developing therapies for the treatment of&nbsp;<strong>Non Muscle Invasive Bladder Cancer&nbsp;<\/strong>with aggregate therapies developed by each company for the same.<\/li>\n<li>Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the&nbsp;<strong>Non Muscle Invasive Bladder Cancer<\/strong>&nbsp;treatment.<\/li>\n<li><strong>Non Muscle Invasive Bladder Cancer&nbsp;<\/strong>key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/li>\n<li>Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/li>\n<li>Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of&nbsp;<strong>Non Muscle Invasive Bladder Cancer<\/strong>&nbsp;market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university web sites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Non Muscle Invasive Bladder Cancer&nbsp;Analytical Perspective by DelveInsight<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>In-depth Non Muscle Invasive Bladder Cancer Commercial Assessment of products&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing\/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Non Muscle Invasive Bladder Cancer Clinical Assessment of products&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The&nbsp;<strong>Non Muscle Invasive Bladder Cancer&nbsp;<\/strong>report provides an overview of&nbsp;<em>therapeutic pipeline activity and therapeutic assessment of the products<\/em>&nbsp;by development stage, product type, route of administration, molecule type, and MOA type&nbsp;<em>for&nbsp;<\/em><strong>Non Muscle Invasive Bladder Cancer&nbsp;<\/strong>across the complete product development cycle, including all clinical and nonclinical stages.<\/li>\n<li>It comprises of&nbsp;<em>detailed profiles of&nbsp;<\/em><strong>Non Muscle Invasive Bladder Cancer&nbsp;<\/strong><em>therapeutic products<\/em>&nbsp;with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details<\/li>\n<li>Detailed&nbsp;<strong>Non Muscle Invasive Bladder Cancer&nbsp;<\/strong><em>research and development progress and trial details<\/em>, results wherever available, are also included in the pipeline study.<\/li>\n<li><em>Coverage of dormant and discontinued pipeline project<\/em>s along with the reasons if available across&nbsp;<strong>Non Muscle Invasive Bladder Cancer<\/strong>.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;Emerging drugs included in the report<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Opdivo (Bristol-Myers Squibb\/Ono Pharmaceuticals)<br \/> 2. UGN-102 (UroGen Pharma)<br \/> 3. TAR200 (TARIS Biomedical)<br \/> 4. ATX 101 (APIM Therapeutics)<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;Table of content<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Non Muscle Invasive Bladder Cancer&nbsp;<\/p>\n<p style=\"text-align: justify;\">3. Non Muscle Invasive Bladder Cancer&nbsp;Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\">3.1. Non Muscle Invasive Bladder Cancer Treatment Guidelines<\/p>\n<p style=\"text-align: justify;\">4. Non Muscle Invasive Bladder Cancer&nbsp;&#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\">6. Non Muscle Invasive Bladder Cancer Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\">7. Non Muscle Invasive Bladder Cancer Mid Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\">8. Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\">12. Non Muscle Invasive Bladder Cancer Discontinued Products<\/p>\n<p style=\"text-align: justify;\">13. Non Muscle Invasive Bladder Cancer&nbsp;Product Profiles<\/p>\n<p style=\"text-align: justify;\">14. Non Muscle Invasive Bladder Cancer&nbsp;Key Companies<\/p>\n<p style=\"text-align: justify;\">15. Non Muscle Invasive Bladder Cancer&nbsp;Key Products<\/p>\n<p style=\"text-align: justify;\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\">17. Non Muscle Invasive Bladder Cancer&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">18. Non Muscle Invasive Bladder Cancer&nbsp;Future Perspectives<\/p>\n<p style=\"text-align: justify;\">19. Non Muscle Invasive Bladder Cancer&nbsp;Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\">21.1. Secondary Research<\/p>\n<p style=\"text-align: justify;\">21.2. Expert Panel Validation&nbsp;<\/p>\n<p style=\"text-align: justify;\">22. About Delveinsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Report<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/non-muscle-invasive-bladder-cancer-market\">Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insight, Epidemiology and Market Forecast &#8211; 2030<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=non-muscle-invasive-bladder-cancer-pipeline-insight-2020\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=non-muscle-invasive-bladder-cancer-pipeline-insight-2020\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(ALBANY, US) DELVEINSIGHT HAS LAUNCHED A NEW REPORT ON&nbsp;Non Muscle Invasive Bladder Cancer Pipeline Non Muscle Invasive Bladder Cancer Pipeline Insight, 2020&nbsp;report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the&nbsp;Non Muscle Invasive Bladder &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/non-muscle-invasive-bladder-cancer-pipeline-insight-2020_496272.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,420,413],"tags":[],"class_list":["post-496272","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Science","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496272"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496272\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}